中国生物制药新药甲磺酸艾立布林注射液获批上市
财中社12月11日电中国生物制药（01177）发布公告称，其开发的“甲磺酸艾立布林注射液”已获得中国国家药品监督管理局的上市批准。该药物主要用于治疗既往接受过至少两种化疗方案的局部晚期或转移性乳腺癌患者，成为国内前三款获批上市的同类药物。
艾立布林作为一种新型非紫杉烷类微管蛋白抑制剂，其作用机制不同于传统的紫杉烷类药物，因此对紫杉醇耐药的患者仍具有效性。公司在乳腺癌领域已有多款产品获批上市，并且在研创新药包括TQB3616、TQB2102和TQB2930等，旨在为乳腺癌患者提供更多优质的治疗选择。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10